Pharmaceuticals
Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration
BEIJING, June 23, 2022 /PRNewswire/ -- Ocumension Therapeutics （1477.HK）announced that the New Drug Application (NDA) for the core product in its pipeline, OT-401 (Sterile non-bioerodible intravitreal implant, Product name: YUTIO), was officially approved by the National Pharmaceutical Administ...
2022-06-23 12:19
2173
A Painless, Micro Injection that One Can Do Oneself with the Latest Chula's Innovation "Detachable and Dissolvable Microneedles"
BANGKOK, June 23, 2022 /PRNewswire/ -- A startup under the umbrella of CU Innovation Hub in collaboration with the Chula Faculty of Science has developed an innovative"Detachable and Dissolvable Microneedle" that makes any injections easy and painless for everyone, while also significantly reduci...
2022-06-23 10:00
2263
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer,Dmitry Samarsky, Ph...
2022-06-22 00:29
2521
Apowiser Raises $1.5M In Seed Funding from Longliv Ventures, a Member of CK Hutchison Holdings, to Expand the Global Reach of its Novel Digital Platform that Empowers Consumers to make Informed Choices when Selecting Over-the-Counter Medications
RA'ANANA, Israel, June 21, 2022 /PRNewswire/ -- Apowiser
2022-06-21 19:00
2123
Fosun's Innovative Achievements Continue to Make Breakthroughs
Thanks to its Robust Global Ecosystem, Fosun's Various Business Segments Continue to Achieve Growth HONG KONG, June 21, 2022 /PRNewswire/ -- With the resumption of work, production, and business operations inShanghai, the 4th 515 Fosun Family Day, which has been ongoing for more than a month, us...
2022-06-21 17:04
2043
Nippon Express Launches New Transport Service Using Environment-friendly Isothermal Packaging
-First Japanese Logistics Company to Collaborate with EMBALL'ISO, Experienced in Vaccine Transport- TOKYO, June 21, 2022 /PRNewswire/ -- Nippon Express Co., Ltd., a group company of Nippon Express Holdings, Inc., has become the first Japanese logistics company to collaborate with EMBALL'ISO, a F...
2022-06-21 14:00
1533
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma
SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, opht...
2022-06-21 08:00
2729
2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines
TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...
2022-06-19 10:30
2946
US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...
2022-06-17 20:00
3600
Global Cord Blood Corporation Announced Cellenkos Receives FDA Clearance of IND Application for CK0804 as Add on Therapy to Ruxolitinib for the Treatment of Myelofibrosis
HONG KONG, June 17, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, is pleased to announce that Cellenkos, Inc. ("CLNK"...
2022-06-17 04:20
2849
111, Inc. Announces First Quarter 2022 Unaudited Financial Results
SHANGHAI, June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quart...
2022-06-16 15:58
4029
Global Pharmaceutical Market Drives Innovative Digitalization to Accelerate Drug Discovery
According to Frost & Sullivan, digitalization across the pharmaceutical value chain will improve the industry´s efficiency. SAN ANTONIO, June 16, 2022 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global Pharmaceuticals Outlook, finds that the accelerated drug development timelines are driv...
2022-06-16 15:12
1950
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
GAITHERSBURG, Md. and SUZHOU, China, June 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead th...
2022-06-16 13:01
2176
GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION
– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV– SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed ...
2022-06-16 11:15
2302
Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022
- The updates of ASC22 Phase IIb study will be presented at the oral session during the International Liver Congress™ 2022 onSaturday, June 25, 2022 at 14:15 , Beijing Time (Abstract Number: OS091) HANGZHOU, China and SHAOXING, China, June 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...
2022-06-16 08:10
2361
Novotech and Medidata expand partnership to continue advancements in clinical research
Leading Asia-Pacific biotech specialist CRO Novotech and Medidata renew partnership, further expanding services to Novotech clients in APAC and the US SINGAPORE, June 16, 2022 /PRNewswire/ -- Medidata, a Dassault Systèmes company, today announced its renewed, expanded partnership with Novotech, a...
2022-06-16 08:00
2293
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...
2022-06-15 22:37
2392
How Global Healthcare Spending and Regulations Boost the Surgical Gloves Market
Demand for environmentally friendly biodegradable surgical gloves unlocks new opportunities for market participants, says Frost & Sullivan SAN ANTONIO, June 15, 2022 /PRNewswire/ -- The increase in healthcare budgets and rise in the number of surgical procedures propel global surgical gloves mar...
2022-06-15 15:12
1572
Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product
* Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered byPierre Fabre targeting solid tumors, from its fill and finish facility in Stein,Switzerland * Pierre Fabre will leverage Lonza's drug product expertise and fill and finish capabilities ...
2022-06-15 14:30
1866
J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria
SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it
will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at
the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna,
Austria from 6th to 9th August.
2022-06-14 22:00
1005
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 310 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 282 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 257 media titles]
2024-05-02 01:21
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
7371
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
6145
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
5052
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
4707
